The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

formationbiologics.com

Stage

Series B | Alive

About Formation Biologics

Formation Biologics is a clinical stage biopharmaceutical company that engineers protein based therapeutics for treatment of cancer and orphan diseases. The company's lead program is AVID100, an antibody-drug conjugate (ADC), intended for the treatment of EGFR-expressing malignancies. The company's second development stage program is AVID200, an isoform-selective TGF-beta inhibitor that is undergoing IND-enabling studies for use in orphan diseases and in immune oncology.

Formation Biologics Headquarter Location

200 E 6th STreet Suite 201

Austin, Texas, 78701,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Formation Biologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Formation Biologics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Formation Biologics Patents

Formation Biologics has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/4/2014

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Clusters of differentiation, Immunology

Application

Application Date

7/4/2014

Grant Date

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Clusters of differentiation, Immunology

Status

Application

Latest Formation Biologics News

2021 Pipeline Insights into Scleroderma - Key Players Include Corbus Pharmaceuticals, Gesynta Pharma and Formation Biologics - ResearchAndMarkets.com

Mar 24, 2021

March 24, 2021 12:49 PM Eastern Daylight Time This report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Scleroderma affects women more often than men and most commonly occurs between the ages of 30 and 50. While there is no cure for scleroderma, a variety of treatments can ease symptoms and improve quality of life. There are many different types of scleroderma. In some people, scleroderma affects only the skin. But in many people, scleroderma also harms structures beyond the skin, such as blood vessels, internal organs and the digestive tract (systemic scleroderma). Scleroderma results from an overproduction and accumulation of collagen in body tissues. There are 2 main types of scleroderma: localised scleroderma - just affects the skin and systemic sclerosis - may affect blood circulation and internal organs as well as the skin. The report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scleroderma pipeline landscape is provided which includes the disease overview and Scleroderma treatment guidelines. The assessment part of the report embraces, in depth Scleroderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scleroderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma. Scleroderma Emerging Drugs Chapters This segment of the Scleroderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Scleroderma Emerging Drugs Lenabasum: Corbus Pharmaceuticals Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. It is currently in Phase III for Systemic scleroderma and is being developed by Corbus Pharmaceuticals. EHP 101: Emerald Health Pharmaceuticals EHP-101 is an oral formulation of a new chemical entity derived from synthetic cannabidiol, also known as CBD, one of the most abundant molecules found in the cannabis plant. The fully synthetic novel molecule formulated in EHP-101 has been rationally designed to enhance the therapeutic benefits of CBD by being a dual peroxisome proliferator-activated receptor gamma (PPAR?) and cannabinoid type 2 receptor (CB2) agonist that also activates the hypoxia inducible factor (HIF) pathway. It is currently in Phase II scleroderma and is being developed by Emerald Health Pharmaceuticals. Scleroderma: Therapeutic Assessment This segment of the report provides insights about the different Scleroderma drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Scleroderma There are approx. 30+ key companies which are developing the therapies for Scleroderma. The companies which have their Scleroderma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer. Phases Late stage products (Phase III) Mid-stage products (Phase II) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates

  • Where is Formation Biologics's headquarters?

    Formation Biologics's headquarters is located at 200 E 6th STreet, Austin.

  • What is Formation Biologics's latest funding round?

    Formation Biologics's latest funding round is Series B.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.